Produktname:4-Chloro-6-(methoxymethyl)-2-phenylpyrimidine
IUPAC Name:4-chloro-6-(methoxymethyl)-2-phenylpyrimidine
- CAS：325685-59-4
- Molekulare Formel：C12H11ClN2O
- Reinheit：95%
- Katalognummer：CM275170
- Molekulargewicht：234.68
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:325685-59-4
- Molekulare Formel:C12H11ClN2O
- Schmelzpunkt:-
- SMILES-Code:COCC1=CC(Cl)=NC(C2=CC=CC=C2)=N1
- Dichte:
- Katalognummer:CM275170
- Molekulargewicht:234.68
- Siedepunkt:
- Mdl-Nr.:
- Lagerung:
Category Infos
- Pyrimidines
- Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Selatogrel
- Selatogrel is an investigational, potent, fast-acting, reversible, and highly selective P2Y12 inhibitor, being developed for the treatment of an acute myocardial infarction (AMI) in patients with a recent history of AMI. It is intended to be self-administered subcutaneously via a drug delivery system (autoinjector).
This novel, self-administered emergency agent has the potential to protect heart muscle in the very early phase of an AMI – in the crucial time between symptom onset and first medical attention – so as to treat the ongoing AMI and prevent early death.
Suche 
+86 21 5895 0110 
